Cvs Health CORP

Market Movers (8-K)

See all →
NYSE
CVS Health announced its intention to separate into two independent, publicly traded companies, a move expected to be completed in the first half of 2028.
NYSE
CVS Health announced robust third-quarter 2026 results, with total revenues climbing 5.4% year-over-year to $108.4 billion, and raised its full-year financial outlook.
Better than expected
NYSE
CVS Health announced the appointment of Teresa Heitsenrether to its Board of Directors, effective November 18, 2026, bringing extensive data and analytics experience, while Larry Robbins departs the board.
NYSE
CVS Health announced robust second quarter 2026 results, with total revenues up 7.3% year-over-year to $106.1 billion, and raised its full-year guidance for EPS and cash flow.
Better than expected
NYSE
CVS Health Corporation's stockholders approved the 2026 Incentive Compensation Plan and ratified the appointment of Ernst & Young LLP as independent auditor at the 2026 Annual Meeting.
NYSE
CVS Health announced robust first-quarter 2026 results, with total revenues reaching $100.4 billion, a 6.2% year-over-year increase, and raised its full-year earnings and cash flow guidance.
Better than expected

Quarterly Earnings (10-Q)

See all →
NYSE
CVS Health Corporation announced robust third-quarter 2026 financial results, showcasing substantial revenue growth and a significant swing to net income, alongside a strategic plan to separate into two independent public companies.
Better than expected
NYSE
CVS Health Corporation announced robust financial results for the second quarter of 2026, showcasing significant revenue growth and a substantial increase in operating income.
Better than expected
NYSE
CVS Health Corporation announced robust financial performance for the first quarter of 2026, with total revenues reaching $100.4 billion, a 6.2% increase year-over-year.
Better than expected
NYSE
CVS Health reported a significant net loss in Q3 2025, primarily driven by a $5.7 billion goodwill impairment charge related to its Health Care Delivery unit, despite overall revenue growth.
Capital raise
Worse than expected
NYSE
CVS Health Corporation reported a significant drop in second-quarter net income and diluted EPS, primarily driven by over $800 million in litigation charges and losses from exiting certain Accountable Care programs, despite overall revenue growth.
Worse than expected
NYSE
CVS Health's Q1 2025 results show significant revenue growth and improved operating income, despite a litigation charge and losses on accountable care assets.
Worse than expected

Annual Reports (10-K)

NYSE
CVS Health reports a 7.8% revenue increase in 2025 to $402.07 billion, driven by growth across all segments, despite a significant goodwill impairment charge and increased litigation expenses impacting net income.
Delay expected
Worse than expected
NYSE
CVS Health Corporation releases its 10-K filing for fiscal year 2024, detailing financial performance and strategic initiatives amidst a changing healthcare industry.
Worse than expected
NYSE
CVS Health Corporation's recent 10-K filing provides a detailed description of its common stock, authorized capital, and compliance with securities regulations.
Worse than expected

Insider Trading (Form 4)

See all →
NYSE
Prem S Shah, EVP and Group President of CVS HEALTH Corp, purchased 23,855 shares of common stock on November 6, 2026 for $83.89 per share.
NYSE
CVS Health Corp. executive James David Clark reported a transaction involving the withholding of common stock to cover FICA taxes upon becoming retirement eligible.
NYSE
CVS Health CFO Brian Newman disposed of 2,478 shares to satisfy tax withholding obligations following a restricted stock unit vesting.
NYSE
CVS Health EVP and Chief Medical Officer Amy Compton-Phillips reported the surrender of 7,618 shares to cover tax obligations.
NYSE
CVS Health Director Fernando Aguirre reported the sale of 19,924 shares of common stock across two transactions in May 2026.
NYSE
Larry Robbins and Glenview Capital have significantly reduced their position in CVS Health through a series of open-market sales.

Proxy Statements (Def-14A)

NYSE
CVS Health Corporation will hold its Annual Meeting of Stockholders on May 15, 2025, with proxy materials available online and via request.
NYSE
CVS Health's 2025 proxy statement highlights strategic priorities, board changes, and executive compensation details.
Delay expected
Worse than expected
NYSE
CVS Health Corporation's upcoming annual meeting on May 16, 2024, will address key proposals including director elections, executive compensation, and amendments to the incentive compensation plan.
NYSE
CVS Health's 2024 proxy statement outlines key governance matters, including director elections, executive compensation, and several stockholder proposals.

Institutional Holdings (13F)

See all →
NYSE
CVS HEALTH Corp reported 36 holdings worth $429.4M for the period ended September 30, 2026.
NYSE
CVS HEALTH Corp reported 21 holdings worth $225.2M for the period ended June 30, 2026.
NYSE
CVS Health Corp. has filed its quarterly 13F holdings report, detailing its investment portfolio as of March 31, 2026, with a total reported value of $212,255,190.
NYSE
CVS Health Corp. filed its Form 13F-HR, revealing over $102 million in equity holdings as of September 30, 2025.
NYSE
CVS Health Corp. has filed its Q2 2025 13F report, revealing equity holdings totaling over $190 million, primarily in the SPDR S&P 500 ETF Trust.
NYSE
CVS Health Corp's latest 13F filing discloses its holdings as of March 31, 2025, showcasing investments in Prudential Financial, Health Catalyst, and SPDR S&P 500 ETF Trust.

Schedule 13G - Passive Investments

See all →
NYSE
Dodge & Cox has reported beneficial ownership of 50,012,765 shares, representing 3.9% of CVS Health Corporation's common stock, as of June 30, 2026.
NYSE
Vanguard Capital Management has filed a Schedule 13G reporting a 7.51% beneficial ownership stake in CVS Health Corp.
NYSE
The Vanguard Group reported a 0% beneficial ownership in CVS Health Corp following an internal realignment, with subsidiaries now reporting separately.
NYSE
BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 8.3% of CVS Health Corporation's common stock as of June 30, 2025.
NYSE
Capital World Investors has filed a Schedule 13G, revealing a beneficial ownership of 5.5% of CVS Health Corp.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 13 to its Schedule 13G, disclosing a 7.1% beneficial ownership stake in CVS Health Corporation as of March 31, 2025.